363 related articles for article (PubMed ID: 26549248)
21. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
Murata J; Abe R; Shimizu H
J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
[TBL] [Abstract][Full Text] [Related]
22. [Stevens-Johnson syndrome and toxic epidermal necrolysis in children].
Sotelo-Cruz N
Gac Med Mex; 2012; 148(3):265-75. PubMed ID: 22820360
[TBL] [Abstract][Full Text] [Related]
23. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ciralsky JB; Sippel KC; Gregory DG
Curr Opin Ophthalmol; 2013 Jul; 24(4):321-8. PubMed ID: 23680755
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.
Barvaliya M; Sanmukhani J; Patel T; Paliwal N; Shah H; Tripathi C
J Postgrad Med; 2011; 57(2):115-9. PubMed ID: 21654132
[TBL] [Abstract][Full Text] [Related]
25. A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Abulatan IT; Ben-David SG; Morales-Colon LA; Beason E; Fakoya AO
Cureus; 2023 Nov; 15(11):e48728. PubMed ID: 38094551
[TBL] [Abstract][Full Text] [Related]
26. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
[TBL] [Abstract][Full Text] [Related]
27. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
28. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
[TBL] [Abstract][Full Text] [Related]
29. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
[TBL] [Abstract][Full Text] [Related]
30. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
Hosaka H; Ohtoshi S; Nakada T; Iijima M
J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
[TBL] [Abstract][Full Text] [Related]
31. New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Saito Y; Abe R
Curr Opin Allergy Clin Immunol; 2023 Aug; 23(4):271-278. PubMed ID: 37284785
[TBL] [Abstract][Full Text] [Related]
32. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
35. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
36. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.
Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP
Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601
[TBL] [Abstract][Full Text] [Related]
37. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.
French LE
Allergol Int; 2006 Mar; 55(1):9-16. PubMed ID: 17075281
[TBL] [Abstract][Full Text] [Related]
38. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series.
Yip LW; Thong BY; Lim J; Tan AW; Wong HB; Handa S; Heng WJ
Allergy; 2007 May; 62(5):527-31. PubMed ID: 17313402
[TBL] [Abstract][Full Text] [Related]
39. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids.
Shammas MC; Lai EC; Sarkar JS; Yang J; Starr CE; Sippel KC
Am J Ophthalmol; 2010 Feb; 149(2):203-213.e2. PubMed ID: 20005508
[TBL] [Abstract][Full Text] [Related]
40. [Erythema multiforme vs. Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction].
Rabelink NM; Brakman M; Maartense E; Bril H; Bakker-Wensveen CA; Bavinck JN
Ned Tijdschr Geneeskd; 2003 Oct; 147(43):2089-94. PubMed ID: 14619195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
